-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
The overall technical application achievements of Guangxiang Pharmaceutical, a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, have reached the internationally advanced level.
Category:
发布时间：2024-07-01
【概要描述】
On June 28, the Science and Technology Achievement Evaluation Center of the Hebei Provincial High-Tech Industry Association convened a panel of relevant experts to conduct an evaluation of the “Application of Membrane Coupling Technology in Active Pharmaceutical Ingredient Production” project undertaken by Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group.
On June 28, the Science and Technology Achievement Evaluation Center of the Hebei Provincial High-Tech Industry Association convened a panel of relevant experts to conduct an evaluation of the “Application of Membrane Coupling Technology in Active Pharmaceutical Ingredient Production” project undertaken by Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group.
The meeting was chaired by Researcher Chen Jingshun, Director of the Evaluation Center of the Provincial High-Tech Industry Association. An evaluation committee comprising four relevant technical experts, including Professor Cao Deying from Hebei Medical University, and one economic expert was invited to attend. The committee heard reports from the project undertaking unit, Guangxiang Pharmaceutical, on the project’s work, technology, and economic benefits, and reviewed supporting documents such as testing reports and novelty search reports. Following questioning and deliberation, the committee unanimously concluded that the project is of great significance for environmental protection and for promoting technological progress within enterprises, boasts broad application prospects, and overall meets internationally advanced standards.
In recent years, Guangxiang Pharmaceutical, a leading API manufacturer within the Group, has placed great emphasis on and vigorously promoted green and clean production. In response to challenges such as wastewater treatment and residual metal elements in API manufacturing, the company has leveraged the characteristics of residues and filtration membranes to drive process and equipment innovation, developing a comprehensive membrane-coupled treatment technology and associated equipment. This breakthrough has enabled the synergistic utilization of wastewater resources, and the implementation of membrane-coupling technology has delivered significant economic and social benefits to the enterprise.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091